Peter Hau
Impact in
- Genetics top 0.01%
- Glioma Diagnosis and Treatment
- Cancer Research top 1%
- Cancer, Hypoxia, and Metabolism
Papers in
- Genetics 155
- Glioma Diagnosis and Treatment 155
-
- Cancer, Hypoxia, and Metabolism 10
- Co-authors
- Michael Weller (9 shared papers)Roger Stupp (5 shared papers)Thierry Gorlia (6 shared papers)Monika E. Hegi (3 shared papers)R.O. Mirimanoff (2 shared papers)Johan M. Kros (2 shared papers)Jacoline E. C. Bromberg (2 shared papers)Johannes Andreas Hainfellner (2 shared papers)
- Journals
- Journal of Neuro-Oncology (20 papers)Neuro-Oncology (19 papers)Cancers (9 papers)The Lancet Oncology (8 papers)PLoS ONE (8 papers)
- Partner nations
- GermanySwitzerlandUnited States
In The Last Decade
Peter Hau
204 papers receiving 23.8k citations
Peter Hau's Hit Papers
Peers
Comparison fields: 5 of 138
- Genetics 16.1k
- Cancer Research 1.5k
- Oncology 2.2k
- Biomaterials 734
- Radiology, Nuclear Medicine and Imaging 1.2k
Countries citing papers authored by Peter Hau
This map shows the geographic impact of Peter Hau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Hau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Hau more than expected).
Fields of papers citing papers by Peter Hau
This network shows the impact of papers produced by Peter Hau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Hau. The network helps show where Peter Hau may publish in the future.
Co-authors
The 25 scholars most cited alongside Peter Hau, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 214 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Hit paper breakdown → | 2009 | 6573 |
| 2 | MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma Hit paper breakdown → | 2005 | 6021 |
| 3 | Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial Hit paper breakdown → | 2017 | 938 |
| 4 | CD133+ and CD133− Glioblastoma-Derived Cancer Stem Cells Show Differential Growth Characteristics and Molecular Profiles Hit paper breakdown → | 2007 | 925 |
| 5 | Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial Hit paper breakdown → | 2014 | 883 |
| 6 | Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial Hit paper breakdown → | 2019 | 439 |
| 7 | 2010 | 371 | |
| 8 | 2010 | 317 | |
| 9 | 2017 | 309 | |
| 10 | 2004 | 294 | |
| 11 | 2015 | 274 | |
| 12 | Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study Hit paper breakdown → | 2021 | 254 |
| 13 | 2008 | 248 | |
| 14 | 2008 | 218 | |
| 15 | 2014 | 218 | |
| 16 | 2016 | 209 | |
| 17 | 2020 | 204 | |
| 18 | 2016 | 187 | |
| 19 | 2007 | 184 | |
| 20 | 2004 | 174 |
About Peter Hau
Peter Hau is a scholar working on Genetics, Cancer Research, Radiology, Nuclear Medicine and Imaging, Oncology and Molecular Biology, having authored 214 papers that have together received 24.4k indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (155 papers), Cancer, Hypoxia, and Metabolism (10 papers), TGF-β signaling in diseases (7 papers), Brain Metastases and Treatment (6 papers), Cancer survivorship and care (5 papers), CNS Lymphoma Diagnosis and Treatment (5 papers), Metabolism, Diabetes, and Cancer (4 papers) and Advanced MRI Techniques and Applications (4 papers). The work is most often cited by research in Genetics (16.1k citations), Cancer Research (1.5k citations), Oncology (2.2k citations), Biomaterials (734 citations) and Radiology, Nuclear Medicine and Imaging (1.2k citations). Peter Hau has collaborated with scholars based in Germany, Switzerland and United States. Frequent co-authors include Michael Weller, Roger Stupp, Thierry Gorlia, Monika E. Hegi, R.O. Mirimanoff, Johan M. Kros, Jacoline E. C. Bromberg, Johannes Andreas Hainfellner, Robert Charles Janzer and Annie‐Claire Diserens. Their work appears in journals such as Journal of Neuro-Oncology, Neuro-Oncology, Cancers, The Lancet Oncology and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.